Proactive Investors
10 Jan 2026, 17:27 UTC · 43w ago
Immunic targets MS market with Phase 3 data - ICYMI
Impact · against what's priced in
The report provides positive clinical data for vidofludimus calcium in progressive MS and extends patent exclusivity to 2041, which significantly enhances the long-term valuation of IMUX. Additionally, early data suggesting GLP-1 pathways for IMU-856 opens a high-value weight management optionality.
- IMUX+0.70
No priced-in read yet
- In context
The phase 2 CALLIPER study's 31% reduction in confirmed disability worsening for progressive MS and the extension of patent exclusivity to 2041 provide strong fundamental catalysts. Early findings on IMU-856 increasing natural GLP-1 levels create a secondary growth vector in weight management.
Read from the article alone
Search tags
